Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) runs in leading trade, it increasing 20.96% to traded at $1.01. MRNS attains analyst recommendation of 2.00 on scale of 1-5 with week’s performance of 16.75%. Marinus Pharmaceuticals, Inc. issued a press release on November 3, 2016 announcing its financial results for the third quarter ended September 30, 2016. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.
The information furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. Except as required by law, we undertake no duty or obligation to publicly update or revise the information so furnished.
To find out the technical position of MRNS, it holds price to book ratio of 0.74 that unearth high-growth companies selling at low-growth prices, but it requires appropriate measurement approach. MRNS is presenting price to cash flow of 0.53. EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at 23.40%, and looking further price to next year’s EPS is 18.20%.
TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) [Trend Analysis] retains strong position in active trade, as shares scoring -46.74% to $0.06 in a active trade session, while looking at the shares volume, around 3.61 Million shares have changed hands in this session. . The firm has institutional ownership of 18.00%, while insider ownership included 35.72%. TLOG attains analyst recommendation of 2.00 with week’s performance of 103.49%.
The co is presenting price to cash flow as 0.19. On other hand, keeping in mind stable cash flows but few growth prospects make traders to value lower. The firm has price volatility of 122.47% for a week and 46.44% for a month. Narrow down four to firm performance, its weekly performance was 103.49% and monthly performance was -18.33%.